Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Number of holders
-
33
-
Total 13F shares, excl. options
-
2,931,208
-
Shares change
-
+420,401
-
Total reported value, excl. options
-
$32,035,175
-
Value change
-
+$4,621,617
-
Number of buys
-
26
-
Number of sells
-
-6
-
Price
-
$10.95
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q2 2019
36 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2019.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 33 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,931,208 shares
of 6,235,531 outstanding shares and own 47.01% of the company stock.
Largest 10 shareholders include Artemis Investment Management LLP (979,015 shares), FMR LLC (706,789 shares), BlackRock Inc. (299,145 shares), CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM (298,400 shares), VANGUARD GROUP INC (259,301 shares), UBS Group AG (75,562 shares), RENAISSANCE TECHNOLOGIES LLC (71,600 shares), GEODE CAPITAL MANAGEMENT, LLC (60,443 shares), NORTHERN TRUST CORP (43,822 shares), and Squarepoint Ops LLC (32,162 shares).
This table shows the top 33 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.